USF-related	B-protein
transcription	I-protein
factor	I-protein
,	O
HIV-TF1	B-protein
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus-1	O
.	O

The	O
transcription	B-protein
factor	I-protein
HIV-TF1	B-protein
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

HIV-TF1	B-protein
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

Binding	O
of	O
HIV-TF1	B-protein
to	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
activated	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O

The	O
HIV-TF1-binding	B-DNA
site	I-DNA
in	O
HIV	B-DNA
LTR	I-DNA
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
(	O
USF	B-protein
)	O
in	O
the	O
adenovirus	B-DNA
major	I-DNA
late	I-DNA
promoter	I-DNA
.	O

DNA-binding	O
properties	O
of	O
HIV-TF1	B-protein
suggested	O
that	O
HIV-TF1	B-protein
might	O
be	O
identical	O
or	O
related	O
to	O
USF	B-protein
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV-TF1	B-protein
by	O
phosphatase	B-protein
greatly	O
reduced	O
its	O
DNA-binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV-TF1	B-protein
was	O
essential	O
for	O
DNA	O
binding	O
.	O

The	O
disruption	O
of	O
HIV-TF1-binding	B-DNA
site	I-DNA
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
HIV-TF1	B-protein
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O

©	NULL
1991	NULL
Oxford	NULL
University	NULL
Press	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

17	NULL
4689-4694	NULL
USF-related	NULL
transcription	NULL
factor	NULL
,	NULL
HIV-TF1	NULL
,	NULL
stimulates	NULL
transcription	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
Toshio	NULL
Maekawa	NULL
``	NULL
,	NULL
Tatsuhiko	NULL
Sudo	NULL
,	NULL
Masashi	NULL
Kurimoto®	NULL
and	NULL
Shunsuke	NULL
Ishii'*	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Tsukuba	NULL
Life	NULL
Science	NULL
Center	NULL
,	NULL
The	NULL
Institute	NULL
of	NULL
Physical	NULL
and	NULL
Chemical	NULL
Research	NULL
,	NULL
RIKEN	NULL
,	NULL
Tsukuba	NULL
,	NULL
Ibaraki	NULL
305	NULL
,	NULL
*Institute	NULL
of	NULL
Medical	NULL
Science	NULL
,	NULL
University	NULL
of	NULL
Tokyo	NULL
,	NULL
4-6-1	NULL
Shirokanedai	NULL
,	NULL
Minato-ku	NULL
,	NULL
Tokyo	NULL
108	NULL
and	NULL
Fujisaki	NULL
Institute	NULL
,	NULL
Hayashibara	NULL
Biochemical	NULL
Laboratories	NULL
Inc.	NULL
,	NULL
675-1	NULL
Fujisaki	NULL
,	NULL
Okayama	NULL
702	NULL
,	NULL
Japan	NULL
Received	NULL
May	NULL
16	NULL
,	NULL
1991	NULL
;	NULL
Revised	NULL
and	NULL
Accepted	NULL
August	NULL
13	NULL
,	NULL
1991	NULL
ABSTRACT	NULL
The	NULL
transcription	NULL
factor	NULL
HIV-TF1	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
a	NULL
region	NULL
about	NULL
60	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
enhancer	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
(	NULL
HIV-1	NULL
)	NULL
,	NULL
was	NULL
purified	NULL
from	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

HIV-TF1	NULL
had	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
39,000	NULL
.	NULL

Binding	NULL
of	NULL
HIV-TF1	NULL
to	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
activated	NULL
transcription	NULL
from	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
HIV-TF1-binding	NULL
site	NULL
in	NULL
HIV	NULL
LTR	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
site	NULL
recognized	NULL
by	NULL
upstream	NULL
stimulatory	NULL
factor	NULL
(	NULL
USF	NULL
)	NULL
in	NULL
the	NULL
adenovirus	NULL
major	NULL
late	NULL
promoter	NULL
.	NULL

DNA-binding	NULL
properties	NULL
of	NULL
HIV-TFA1	NULL
suggested	NULL
that	NULL
HIV-TF1	NULL
might	NULL
be	NULL
identical	NULL
or	NULL
related	NULL
to	NULL
USF	NULL
.	NULL

Interestingly	NULL
,	NULL
treatment	NULL
of	NULL
purified	NULL
HIV-TF1	NULL
by	NULL
phosphatase	NULL
greatly	NULL
reduced	NULL
its	NULL
DNA-binding	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
of	NULL
HIV-TF1	NULL
was	NULL
essential	NULL
for	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
disruption	NULL
of	NULL
HIV-TF1-binding	NULL
site	NULL
induced	NULL
a	NULL
60	NULL
%	NULL
decrease	NULL
in	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
from	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
vivo	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
HIV-TF1i	NULL
is	NULL
involved	NULL
in	NULL
transcriptional	NULL
regulation	NULL
of	NULL
HIV-1	NULL
.	NULL

INTRODUCTION	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
is	NULL
a	NULL
cytopathic	NULL
retrovirus	NULL
and	NULL
is	NULL
the	NULL
etiologic	NULL
agent	NULL
of	NULL
the	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
(	NULL
1-4	NULL
)	NULL
.	NULL

Transcription	NULL
of	NULL
HIV	NULL
is	NULL
regulated	NULL
by	NULL
viral	NULL
proteins	NULL
such	NULL
as	NULL
Tat	NULL
(	NULL
5-7	NULL
)	NULL
and	NULL
also	NULL
by	NULL
cellular	NULL
transcription	NULL
factors	NULL
(	NULL
8-11	NULL
)	NULL
.	NULL

Two	NULL
regulatory	NULL
regions	NULL
in	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
,	NULL
the	NULL
enhancer	NULL
and	NULL
TAR	NULL
regions	NULL
,	NULL
are	NULL
important	NULL
for	NULL
regulation	NULL
by	NULL
the	NULL
enhancer-binding	NULL
protein	NULL
(	NULL
EBP	NULL
)	NULL
and	NULL
the	NULL
viral	NULL
trans-activator	NULL
Tat	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
regulatory	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
is	NULL
induced	NULL
by	NULL
compounds	NULL
such	NULL
as	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
or	NULL
phorbol	NULL
ester	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

This	NULL
process	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
a	NULL
key	NULL
step	NULL
for	NULL
HIV	NULL
production	NULL
from	NULL
latently	NULL
infected	NULL
T	NULL
lymphocytes	NULL
.	NULL

Multiple	NULL
proteins	NULL
were	NULL
identified	NULL
as	NULL
the	NULL
HIV	NULL
EBP	NULL
:	NULL
NF-xB	NULL
consisting	NULL
of	NULL
a	NULL
50	NULL
kDa	NULL
and	NULL
65	NULL
kDa	NULL
polypeptide	NULL
(	NULL
13	NULL
)	NULL
,	NULL
51-kDa	NULL
NF-xB	NULL
from	NULL
Namalwa	NULL
Burkit	NULL
lymphoma	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
,	NULL
48-kDa	NULL
KBF-1	NULL
from	NULL
mouse	NULL
BW5147	NULL
thymoma	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
,	NULL
36-42	NULL
kDa	NULL
polypeptides	NULL
from	NULL
human	NULL
BALL-1	NULL
B	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
,	NULL
H2TF1	NULL
found	NULL
in	NULL
many	NULL
types	NULL
of	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
,	NULL
57-60	NULL
kDa	NULL
EBP-1	NULL
from	NULL
HeLa	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
,	NULL
and	NULL
86-kDa	NULL
HIVEN	NULL
86	NULL
found	NULL
in	NULL
activated	NULL
human	NULL
T-cells	NULL
(	NULL
19	NULL
)	NULL
.	NULL

NF-xB	NULL
localized	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
sequestered	NULL
form	NULL
is	NULL
dissociated	NULL
from	NULL
its	NULL
inhibitor	NULL
IxB	NULL
by	NULL
phosphorylation	NULL
of	NULL
IxB	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

Differences	NULL
between	NULL
H2TFI	NULL
and	NULL
NF-xB	NULL
were	NULL
noted	NULL
in	NULL
their	NULL
contacts	NULL
with	NULL
DNA	NULL
,	NULL
their	NULL
relative	NULL
affinity	NULL
with	NULL
the	NULL
related	NULL
sequences	NULL
,	NULL
their	NULL
inducibility	NULL
,	NULL
and	NULL
cell	NULL
type	NULL
distribution	NULL
(	NULL
13	NULL
,	NULL
14	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
cDNA	NULL
clones	NULL
encoding	NULL
two	NULL
types	NULL
of	NULL
HIV	NULL
EBP	NULL
were	NULL
isolated	NULL
.	NULL

HIV-EP1/PRDII-BF1I/MBP-1	NULL
has	NULL
a	NULL
relative	NULL
molecular	NULL
mass	NULL
of	NULL
298	NULL
kDa	NULL
,	NULL
and	NULL
contains	NULL
two	NULL
zine	NULL
fingers	NULL
in	NULL
the	NULL
DNA-binding	NULL
domain	NULL
(	NULL
23-25	NULL
)	NULL
.	NULL

The	NULL
related	NULL
proteins	NULL
were	NULL
also	NULL
identified	NULL
by	NULL
cDNA	NULL
cloning	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
mRNAs	NULL
encoding	NULL
these	NULL
proteins	NULL
is	NULL
induced	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
mitogen	NULL
and	NULL
phorbol	NULL
ester	NULL
(	NULL
25	NULL
,	NULL
27	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
cDNA	NULL
cloning	NULL
of	NULL
the	NULL
DNA-binding	NULL
subumit	NULL
(	NULL
p50	NULL
)	NULL
of	NULL
NF-xB	NULL
indicated	NULL
that	NULL
its	NULL
DNA-biding	NULL
domain	NULL
had	NULL
a	NULL
homology	NULL
with	NULL
the	NULL
rel	NULL
oncoprotein	NULL
and	NULL
Drosophila	NULL
dorsal	NULL
gene	NULL
product	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
two	NULL
different	NULL
types	NULL
of	NULL
proteins	NULL
,	NULL
the	NULL
metal-finger	NULL
protein	NULL
and	NULL
the	NULL
re/-related	NULL
protein	NULL
,	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
,	NULL
but	NULL
the	NULL
mechanism	NULL
of	NULL
activation	NULL
by	NULL
mitogen	NULL
and	NULL
phorbol	NULL
ester	NULL
is	NULL
different	NULL
between	NULL
these	NULL
two	NULL
types	NULL
of	NULL
proteins	NULL
.	NULL

Another	NULL
putative	NULL
regulatory	NULL
region	NULL
(	NULL
nucleotides	NULL
-159	NULL
to	NULL
-173	NULL
)	NULL
upstream	NULL
from	NULL
the	NULL
enhancer	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
was	NULL
identified	NULL
by	NULL
DNase	NULL
I	NULL
footprinting	NULL
with	NULL
HeLa	NULL
cell	NULL
extracts	NULL
(	NULL
10	NULL
)	NULL
.	NULL

This	NULL
region	NULL
was	NULL
also	NULL
pointed	NULL
out	NULL
to	NULL
contain	NULL
a	NULL
sequence	NULL
similar	NULL
to	NULL
the	NULL
site	NULL
for	NULL
upstream	NULL
stimulatory	NULL
factor	NULL
(	NULL
USF	NULL
)	NULL
in	NULL
the	NULL
adenovirus	NULL
major	NULL
late	NULL
promoter	NULL
(	NULL
Ad	NULL
MLP	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

So	NULL
far	NULL
,	NULL
however	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
role	NULL
of	NULL
this	NULL
site	NULL
and	NULL
the	NULL
regulatory	NULL
protein	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
report	NULL
the	NULL
purification	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
HIV-TF1	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
.	NULL

HIV-TFI	NULL
also	NULL
bound	NULL
to	NULL
the	NULL
USF	NULL
site	NULL
in	NULL
Ad	NULL
MLP	NULL
.	NULL

Interestingly	NULL
,	NULL
phosphorylation	NULL
of	NULL
HIV-TFI1	NULL
was	NULL
required	NULL
for	NULL
its	NULL
DNA	NULL
binding	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
4690	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

17	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Purification	NULL
of	NULL
HIV-TF1	NULL
HIV-TF1	NULL
was	NULL
purified	NULL
from	NULL
whole	NULL
cell	NULL
extract	NULL
(	NULL
WCE	NULL
)	NULL
of	NULL
human	NULL
B	NULL
cells	NULL
,	NULL
BALL-1	NULL
,	NULL
using	NULL
heparin-Sepharose	NULL
and	NULL
sequence-specific	NULL
affinity	NULL
column	NULL
chromatography	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

A	NULL
oligonucleotide	NULL
column	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
by	NULL
Kadonaga	NULL
and	NULL
Tjian	NULL
(	NULL
31	NULL
)	NULL
with	NULL
the	NULL
synthetic	NULL
duplex	NULL
oligonucleotides	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

DNA	NULL
binding	NULL
assay	NULL
and	NULL
photoaffinity	NULL
labeling	NULL
The	NULL
gel	NULL
retardation	NULL
assay	NULL
and	NULL
DNase	NULL
I	NULL
footprinting	NULL
were	NULL
done	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

For	NULL
the	NULL
gel	NULL
retardation	NULL
assay	NULL
,	NULL
the	NULL
synthetic	NULL
duplex	NULL
oligonucleotides	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
were	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

For	NULL
the	NULL
DNase	NULL
I	NULL
footprinting	NULL
,	NULL
the	NULL
Bg/Il-EcoRV	NULL
fragment	NULL
(	NULL
nucleotides	NULL
+23	NULL
to	NULL
-338	NULL
in	NULL
the	NULL
HIV-1	NULL
recombinant	NULL
,	NULL
pCD12	NULL
(	NULL
32	NULL
)	NULL
)	NULL
was	NULL
P-labeled	NULL
at	NULL
the	NULL
5	NULL
end	NULL
of	NULL
the	NULL
upper	NULL
strand	NULL
.	NULL

Photoaffinity	NULL
labeling	NULL
was	NULL
done	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

(	NULL
33	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
Transcription	NULL
using	NULL
HeLa	NULL
WCE	NULL
was	NULL
done	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
except	NULL
for	NULL
that	NULL
0.5	NULL
ug	NULL
of	NULL
HIV-1	NULL
template	NULL
DNA	NULL
and	NULL
0.5	NULL
ug	NULL
of	NULL
control	NULL
template	NULL
DNA	NULL
were	NULL
used	NULL
.	NULL

The	NULL
EcoRI-cut	NULL
pCD12	NULL
plasmid	NULL
DNA	NULL
containing	NULL
the	NULL
HIV-1	NULL
promoter	NULL
was	NULL
used	NULL
as	NULL
a	NULL
template	NULL
.	NULL

The	NULL
EcoRI-cut	NULL
pRSVCAT	NULL
plasmid	NULL
DNA	NULL
in	NULL
which	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
(	NULL
RSV	NULL
)	NULL
LTR	NULL
promoter	NULL
is	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
was	NULL
used	NULL
as	NULL
the	NULL
control	NULL
template	NULL
.	NULL

Run-off	NULL
transcripts	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
7	NULL
M	NULL
urea/4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
each	NULL
transcript	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
a	NULL
Bioimage	NULL
Analyzer	NULL
(	NULL
Fuji	NULL
Photo	NULL
Film	NULL
Co.	NULL
,	NULL
Ltd.	NULL
)	NULL
.	NULL

Mutant	NULL
plasmid	NULL
construction	NULL
,	NULL
DNA	NULL
transfection	NULL
,	NULL
and	NULL
CAT	NULL
assay	NULL
The	NULL
HIV-TFl-binding	NULL
site	NULL
in	NULL
the	NULL
HIV	NULL
LTR	NULL
was	NULL
disrupted	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
HindIII	NULL
fragment	NULL
(	NULL
nucleotides	NULL
+82	NULL
to	NULL
-190	NULL
)	NULL
containing	NULL
the	NULL
HIV	NULL
promoter	NULL
was	NULL
generated	NULL
from	NULL
the	NULL
plasmid	NULL
pCD12	NULL
by	NULL
the	NULL
method	NULL
of	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
,	NULL
and	NULL
then	NULL
the	NULL
HindIII	NULL
fragment	NULL
containing	NULL
the	NULL
whole	NULL
region	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
in	NULL
pCD12	NULL
was	NULL
replaced	NULL
by	NULL
this	NULL
272-bp	NULL
HindIII	NULL
fragment	NULL
to	NULL
generate	NULL
the	NULL
plasmid	NULL
pCD-190	NULL
.	NULL

By	NULL
using	NULL
the	NULL
primer	NULL
corresponding	NULL
to	NULL
the	NULL
mutant	NULL
sequence	NULL
of	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
at	NULL
nucleotide	NULL
-166	NULL
,	NULL
the	NULL
mutant	NULL
plasmid	NULL
pCD-190TF	NULL
1m	NULL
was	NULL
constructed	NULL
similarly	NULL
.	NULL

For	NULL
the	NULL
CAT	NULL
assay	NULL
,	NULL
the	NULL
plasmid	NULL
pCD-190	NULL
and	NULL
the	NULL
mutant	NULL
plasmid	NULL
pCD-190TF1m	NULL
harboring	NULL
the	NULL
disrupted	NULL
HIV-TFI-binding	NULL
site	NULL
were	NULL
used	NULL
.	NULL

Mixtures	NULL
of	NULL
each	NULL
CAT	NULL
plasmid	NULL
DNA	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
pRSV-B-gal	NULL
plasmid	NULL
DNA	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
by	NULL
electroporation	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
pRSV-B-gal	NULL
,	NULL
which	NULL
carries	NULL
the	NULL
E.	NULL
coli	NULL
B-galactosidase	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
RSV	NULL
LTR	NULL
(	NULL
35	NULL
)	NULL
was	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
differences	NULL
in	NULL
transfection	NULL
efficiency	NULL
between	NULL
precipitates	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
done	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
cell	NULL
extract	NULL
used	NULL
for	NULL
CAT	NULL
assays	NULL
were	NULL
normalized	NULL
with	NULL
respect	NULL
to	NULL
B-galactosidase	NULL
activity	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
conversion	NULL
was	NULL
measured	NULL
by	NULL
the	NULL
density	NULL
of	NULL
the	NULL
spot	NULL
corresponding	NULL
to	NULL
either	NULL
unreacted	NULL
|	NULL
!	NULL

4C	NULL
chloramphenicol	NULL
or	NULL
its	NULL
accetylated	NULL
forms	NULL
using	NULL
a	NULL
Bioimage	NULL
analyzer	NULL
(	NULL
Fuji	NULL
Photo	NULL
Film	NULL
Co.	NULL
,	NULL
Ltd.	NULL
)	NULL
.	NULL

Phosphatase	NULL
treatment	NULL
Purified	NULL
HIV-TFI	NULL
or	NULL
HIV	NULL
EBP	NULL
was	NULL
treated	NULL
with	NULL
potato	NULL
acid	NULL
phosphatase	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

Purified	NULL
protein	NULL
(	NULL
2	NULL
ng	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
8x	NULL
10-5	NULL
units	NULL
of	NULL
phosphatase	NULL
in	NULL
15	NULL
pl	NULL
of	NULL
gel	NULL
retardation-binding	NULL
buffer	NULL
[	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
.	NULL

1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
100	NULL
ug/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
5	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol	NULL
]	NULL
for	NULL
20	NULL
min	NULL
at	NULL
30°C	NULL
.	NULL

The	NULL
P-labeled	NULL
probe	NULL
was	NULL
then	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
25°C	NULL
,	NULL
and	NULL
the	NULL
material	NULL
was	NULL
analyzed	NULL
by	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
in	NULL
low	NULL
ionic	NULL
strength	NULL
.	NULL

RESULTS	NULL
Purification	NULL
of	NULL
HIV-TFI	NULL
HIV-TF	NULL
!	NULL

I	NULL
was	NULL
purified	NULL
by	NULL
chromatography	NULL
on	NULL
(	NULL
i	NULL
)	NULL
heparin-Sepharose	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
specific	NULL
oligo-DNA	NULL
Sepharose	NULL
.	NULL

The	NULL
WCE	NULL
from	NULL
BALL-1	NULL
cells	NULL
were	NULL
fractionated	NULL
with	NULL
heparin-Sepharose	NULL
column	NULL
chromatography	NULL
,	NULL
and	NULL
the	NULL
fractions	NULL
were	NULL
used	NULL
in	NULL
the	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

The	NULL
synthetic	NULL
duplex	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
nucleotides	NULL
-	NULL
177	NULL
to	NULL
-	NULL
151	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
were	NULL
4	NULL
di	NULL
Figure	NULL
1	NULL
.	NULL

Purification	NULL
of	NULL
HIV-TFI	NULL
.	NULL

A	NULL
,	NULL
Fractions	NULL
from	NULL
the	NULL
oligo-DNA	NULL
Sepharose	NULL
column	NULL
were	NULL
assayed	NULL
by	NULL
gel	NULL
retardation	NULL
with	NULL
the	NULL
probe	NULL
shown	NULL
in	NULL
B	NULL
.	NULL

B	NULL
,	NULL
Fractions	NULL
from	NULL
the	NULL
oligo-DNA	NULL
Sepharose	NULL
column	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-polyacrylamide	NULL
ge	NULL
!	NULL

electrophoresis	NULL
followed	NULL
by	NULL
silver	NULL
staining	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
oligonucleotides	NULL
used	NULL
as	NULL
a	NULL
ligand	NULL
is	NULL
shown	NULL
above	NULL
.	NULL

C	NULL
,	NULL
Ten	NULL
ng	NULL
of	NULL
the	NULL
affinity-purified	NULL
fraction	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
5-bromodeoxy-uridine-substituted	NULL
specific	NULL
oligonucleotide	NULL
probe	NULL
shown	NULL
in	NULL
B.	NULL
UV	NULL
cross-linked	NULL
.	NULL

digested	NULL
with	NULL
nuclease	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
an	NULL
SDS-polyacrylamide	NULL
gel	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
without	NULL
purified	NULL
fraction	NULL
.	NULL

Lane	NULL
3	NULL
,	NULL
with	NULL
40	NULL
ng	NULL
(	NULL
100-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
specific	NULL
oligonucleotide	NULL
as	NULL
a	NULL
competitor	NULL
.	NULL

Molecular	NULL
weights	NULL
of	NULL
markers	NULL
and	NULL
protein-DNA	NULL
adducts	NULL
are	NULL
shown	NULL
on	NULL
the	NULL
right	NULL
and	NULL
left	NULL
.	NULL

respectively	NULL
.	NULL

A	NULL
HIV-TF1	NULL
+	NULL
#	NULL
+	NULL
++	NULL
EBP	NULL
--	NULL
o	NULL
W	NULL
``	NULL
-~~~	NULL
#	NULL
t	NULL
as	NULL
as	NULL
an	NULL
an	NULL
W	NULL
105	NULL
a	NULL
@	NULL
C	NULL
&	NULL
ous	NULL
1	NULL
41-AIH	NULL
DOVLOLOVILONYVVILD	NULL
b	NULL
id	NULL
#	NULL
%	NULL
@	NULL
1	NULL
%	NULL
€	NULL
U	NULL
1	NULL
I	NULL
$	NULL
j99oueyua	NULL
``	NULL
*	NULL
-	NULL
an	NULL
an	NULL
oss	NULL
--	NULL
o	NULL
C	NULL
free	NULL
probe	NULL
-	NULL
»	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

17	NULL
4691	NULL
USF	NULL
site	NULL
in	NULL
Ad	NULL
MLP	NULL
GGCCACGTGA	NULL
HIV-TF1	NULL
site	NULL
in	NULL
HIV	NULL
LTR	NULL
__	NULL
--	NULL
--	NULL
~-Ad	NULL
MLP	NULL
competitor	NULL
-	NULL
-	NULL
-e	NULL
-	NULL
of	NULL
~	NULL
HIV	NULL
competitor	NULL
-	NULL
-	NULL
o	NULL
-	NULL
-	NULL
-	NULL
HIV-TF1	NULL
_-	NULL
+o	NULL
+o	NULL
to	NULL
kok	NULL
-o	NULL
o+	NULL
1	NULL
20	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
%	NULL
DNA-protein	NULL
I	NULL
|	NULL
complex	NULL
weet	NULL
44	NULL
4	NULL
probe	NULL
HIV	NULL
Ad	NULL
MLP	NULL
Figure	NULL
2	NULL
.	NULL

DNA-binding	NULL
property	NULL
of	NULL
HIV-TF1	NULL
.	NULL

A	NULL
,	NULL
DNase	NULL
I	NULL
footprinting	NULL
with	NULL
purified	NULL
HIV-TFI1	NULL
and	NULL
HIV	NULL
EBP	NULL
.	NULL

End-labeled	NULL
Bg/II-EcoRV	NULL
DNA	NULL
fragment	NULL
from	NULL
pCD12	NULL
plasmid	NULL
was	NULL
incubated	NULL
with	NULL
purified	NULL
HIV-TFI	NULL
(	NULL
4	NULL
ng/ul	NULL
)	NULL
and	NULL
HIV	NULL
EBP	NULL
(	NULL
5	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
two	NULL
factors	NULL
used	NULL
was	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
;	NULL
+	NULL
,	NULL
3	NULL
pl	NULL
and	NULL
++	NULL
,	NULL
6	NULL
ul	NULL
.	NULL

After	NULL
treatment	NULL
with	NULL
DNase	NULL
,	NULL
the	NULL
DNA	NULL
was	NULL
purified	NULL
and	NULL
analyzed	NULL
on	NULL
an	NULL
8	NULL
%	NULL
sequencing	NULL
gel	NULL
.	NULL

The	NULL
protected	NULL
region	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
brackets	NULL
.	NULL

B	NULL
,	NULL
Binding	NULL
of	NULL
HIV-TFI	NULL
to	NULL
the	NULL
USF	NULL
site	NULL
in	NULL
the	NULL
Ad	NULL
MLP	NULL
.	NULL

At	NULL
the	NULL
top	NULL
,	NULL
DNA	NULL
sequence	NULL
of	NULL
HIV-TF1-binding	NULL
site	NULL
in	NULL
the	NULL
HIV	NULL
LTR	NULL
and	NULL
USF-binding	NULL
site	NULL
in	NULL
the	NULL
Ad	NULL
MLP	NULL
is	NULL
indicated	NULL
.	NULL

Dash	NULL
of	NULL
HIV-TFI1	NULL
site	NULL
shows	NULL
the	NULL
same	NULL
sequence	NULL
as	NULL
that	NULL
of	NULL
USF	NULL
site	NULL
.	NULL

The	NULL
purified	NULL
HIV-TF1	NULL
was	NULL
used	NULL
for	NULL
a	NULL
gel	NULL
retardation	NULL
assay	NULL
with	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
containing	NULL
the	NULL
sequence	NULL
of	NULL
HIV	NULL
LTR	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
(	NULL
lanes	NULL
1-6	NULL
)	NULL
or	NULL
the	NULL
USF-binding	NULL
site	NULL
of	NULL
Ad	NULL
MLP	NULL
(	NULL
5°GATCAGGTGTAGGCCACGTGACCGGGTGTTCC3	NULL
'	NULL
,	NULL
3'TCCACATCCGGTGCACTGGCCCACAAGGCTAGS	NULL
'	NULL
)	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
without	NULL
purified	NULL
HIV-TF1	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
with	NULL
20-	NULL
and	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
HIV	NULL
oligonucleotide	NULL
as	NULL
a	NULL
competitor	NULL
,	NULL
respectively	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
,	NULL
with	NULL
20-	NULL
and	NULL
100-fold	NULL
molar	NULL
excess	NULL
amount	NULL
of	NULL
Ad	NULL
MLP	NULL
oligonucleotide	NULL
as	NULL
a	NULL
competitor	NULL
,	NULL
respectively	NULL
.	NULL

used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

The	NULL
binding	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
fractions	NULL
corresponding	NULL
to	NULL
0.4-0.5	NULL
M	NULL
KCl	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
fraction	NULL
was	NULL
then	NULL
put	NULL
on	NULL
an	NULL
oligo-DNA	NULL
Sepharose	NULL
column	NULL
,	NULL
in	NULL
which	NULL
the	NULL
same	NULL
duplex	NULL
oligonucleotides	NULL
as	NULL
those	NULL
used	NULL
in	NULL
the	NULL
gel	NULL
retardation	NULL
assay	NULL
were	NULL
used	NULL
as	NULL
a	NULL
ligand	NULL
,	NULL
and	NULL
the	NULL
binding	NULL
factor	NULL
was	NULL
eluted	NULL
by	NULL
increases	NULL
in	NULL
the	NULL
KCl	NULL
concentration	NULL
.	NULL

The	NULL
binding	NULL
factor	NULL
was	NULL
detected	NULL
in	NULL
fractions	NULL
10-18	NULL
corresponding	NULL
to	NULL
0.5-0.6	NULL
M	NULL
KCI	NULL
,	NULL
which	NULL
included	NULL
39	NULL
and	NULL
40	NULL
kDa	NULL
polypeptides	NULL
as	NULL
the	NULL
major	NULL
protein	NULL
and	NULL
other	NULL
minor	NULL
polypeptides	NULL
of	NULL
70-80	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
bands	NULL
between	NULL
65	NULL
and	NULL
50	NULL
kDa	NULL
corresponded	NULL
to	NULL
a	NULL
silver	NULL
staining	NULL
artifact	NULL
.	NULL

About	NULL
10	NULL
ug	NULL
of	NULL
polypeptides	NULL
of	NULL
39	NULL
and	NULL
40	NULL
kDa	NULL
(	NULL
HIV-TF1	NULL
)	NULL
was	NULL
purified	NULL
from	NULL
100	NULL
g	NULL
of	NULL
BALL-1	NULL
cells	NULL
.	NULL

To	NULL
examine	NULL
which	NULL
polypeptide	NULL
binds	NULL
specifically	NULL
to	NULL
the	NULL
sequence	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
we	NULL
used	NULL
UV	NULL
cross-linking	NULL
.	NULL

The	NULL
photoaffinity	NULL
labeling	NULL
probe	NULL
was	NULL
prepared	NULL
from	NULL
the	NULL
oligonucleotide	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

After	NULL
incubating	NULL
the	NULL
DNA	NULL
probe	NULL
with	NULL
the	NULL
purified	NULL
factor	NULL
,	NULL
the	NULL
mixture	NULL
was	NULL
exposed	NULL
to	NULL
UV	NULL
light	NULL
,	NULL
digested	NULL
with	NULL
nuclease	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
SDS-polyacrylamide	NULL
gel	NULL
.	NULL

We	NULL
observed	NULL
the	NULL
protein-DNA	NULL
adduct	NULL
of	NULL
about	NULL
45	NULL
kDa	NULL
as	NULL
a	NULL
major	NULL
band	NULL
that	NULL
was	NULL
resistant	NULL
to	NULL
further	NULL
increases	NULL
in	NULL
DNase	NULL
digestion	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

In	NULL
a	NULL
competition	NULL
experiment	NULL
an	NULL
unlabeled	NULL
specific	NULL
oligonucleotide	NULL
abolished	NULL
the	NULL
signal	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Omission	NULL
of	NULL
purified	NULL
facror	NULL
from	NULL
the	NULL
reaction	NULL
also	NULL
failed	NULL
to	NULL
produce	NULL
any	NULL
signal	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicated	NULL
that	NULL
two	NULL
polypeptides	NULL
of	NULL
39	NULL
and/or	NULL
40	NULL
kDa	NULL
had	NULL
a	NULL
binding	NULL
activity	NULL
.	NULL

EBP	NULL
_	NULL
0	NULL
2525	NULL
0	NULL
0	NULL
pul	NULL
_	NULL
.	NULL

20	NULL
HIV-TF1	NULL
0	NULL
0	NULL
2525	NULL
4	NULL
u	NULL
€	NULL
20	NULL
5	NULL
G	NULL
G	NULL
0	NULL
;	NULL
o	NULL
pCD12	NULL
-	NULL
<	NULL
<	NULL
des	NULL
g	NULL
RSV-CAT	NULL
-+-	NULL
v	NULL
non	NULL
er	NULL
Sigh	NULL
6	NULL
N	NULL
a	NULL
.	NULL

«	NULL
alld	NULL
wed	NULL
@	NULL
.2	NULL
R	NULL
C	NULL
O	NULL
CC	NULL
Figure	NULL
3	NULL
.	NULL

Stimulation	NULL
of	NULL
transcription	NULL
from	NULL
HIV	NULL
promoter	NULL
by	NULL
purified	NULL
HIV-TF1	NULL
in	NULL
vitro	NULL
.	NULL

Transcription	NULL
was	NULL
done	NULL
with	NULL
EcoRI-cut	NULL
pCD12	NULL
as	NULL
a	NULL
DNA	NULL
template	NULL
.	NULL

The	NULL
EcoRI-cut	NULL
pRSVCAT	NULL
DNA	NULL
was	NULL
used	NULL
as	NULL
the	NULL
control	NULL
template	NULL
.	NULL

Each	NULL
reaction	NULL
contained	NULL
variable	NULL
amouts	NULL
of	NULL
purified	NULL
HIV-TF1	NULL
(	NULL
4	NULL
and	NULL
HIV	NULL
EBP	NULL
(	NULL
5	NULL
as	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

The	NULL
locations	NULL
of	NULL
the	NULL
run-off	NULL
transcripts	NULL
of	NULL
373	NULL
nucleotides	NULL
from	NULL
the	NULL
HIV	NULL
promoter	NULL
and	NULL
that	NULL
of	NULL
291	NULL
nucleotides	NULL
from	NULL
the	NULL
RSV	NULL
promoter	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

The	NULL
multiple	NULL
transcripts	NULL
in	NULL
the	NULL
lower	NULL
part	NULL
of	NULL
gel	NULL
were	NULL
generated	NULL
by	NULL
degradation	NULL
of	NULL
the	NULL
transcripts	NULL
from	NULL
the	NULL
HIV	NULL
promoter	NULL
or	NULL
premature	NULL
termination	NULL
of	NULL
transcription	NULL
from	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

On	NULL
the	NULL
right	NULL
,	NULL
the	NULL
results	NULL
of	NULL
in	NULL
vitro	NULL
transcription	NULL
are	NULL
indicated	NULL
by	NULL
a	NULL
bar	NULL
graph	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
373-nucleotides	NULL
transcripts	NULL
were	NULL
normalized	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
amounts	NULL
of	NULL
291-nucleotides	NULL
transcripts	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
HIV-1	NULL
promoter	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
HIV-TFI	NULL
and/or	NULL
HIV	NULL
EBP	NULL
is	NULL
expressed	NULL
relative	NULL
to	NULL
that	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
factors	NULL
.	NULL

4692	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

17	NULL
h	NULL
A	NULL
_	NULL
@	NULL
€	NULL
&	NULL
#	NULL
Figure	NULL
4	NULL
.	NULL

Effects	NULL
of	NULL
disruption	NULL
of	NULL
HIV-TF1	NULL
site	NULL
on	NULL
CAT	NULL
activity	NULL
directed	NULL
by	NULL
HIV	NULL
promoter-CAT	NULL
.	NULL

A	NULL
,	NULL
Transcriptional	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
pCD-190	NULL
plasmid	NULL
,	NULL
in	NULL
which	NULL
the	NULL
HIV	NULL
LTR	NULL
was	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
,	NULL
are	NULL
indicated	NULL
at	NULL
the	NULL
top	NULL
.	NULL

Two	NULL
nucleotides	NULL
of	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
in	NULL
pCD-190	NULL
were	NULL
changed	NULL
to	NULL
generate	NULL
the	NULL
plasmid	NULL
pCD-190TFIm	NULL
.	NULL

B	NULL
,	NULL
Mixtures	NULL
of	NULL
pCD-190	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
or	NULL
pCD-190TFIm	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
and	NULL
pRSV-G-gal	NULL
plasmid	NULL
DNA	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Amount	NULL
of	NULL
CAT	NULL
plasmid	NULL
DNA	NULL
used	NULL
was	NULL
15	NULL
ug	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
7.5	NULL
ug	NULL
(	NULL
lanes	NULL
3-8	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PHA	NULL
(	NULL
2	NULL
ug/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
10mM	NULL
)	NULL
for	NULL
20	NULL
h	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
or	NULL
8	NULL
h	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
before	NULL
harvest	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Experiments	NULL
were	NULL
repeated	NULL
three	NULL
times	NULL
,	NULL
and	NULL
typical	NULL
results	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
differences	NULL
between	NULL
each	NULL
set	NULL
of	NULL
experiments	NULL
were	NULL
within	NULL
10	NULL
%	NULL
.	NULL

CAT	NULL
activity	NULL
of	NULL
pCD-190TFIim	NULL
was	NULL
shown	NULL
above	NULL
each	NULL
lane	NULL
relative	NULL
to	NULL
that	NULL
of	NULL
pCD-190	NULL
under	NULL
same	NULL
assay	NULL
conditions	NULL
.	NULL

C	NULL
,	NULL
Gel	NULL
retardation	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
using	NULL
the	NULL
wild-type	NULL
probe	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
or	NULL
the	NULL
mutant	NULL
probe	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
mutant	NULL
probe	NULL
is	NULL
the	NULL
same	NULL
as	NULL
the	NULL
wild-type	NULL
probe	NULL
except	NULL
for	NULL
2	NULL
nucleotides	NULL
as	NULL
shown	NULL
in	NULL
A	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
HIV-TF1	NULL
used	NULL
are	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

We	NULL
also	NULL
did	NULL
renaturation	NULL
experiments	NULL
after	NULL
the	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

After	NULL
isolation	NULL
and	NULL
renaturation	NULL
,	NULL
only	NULL
the	NULL
protein	NULL
samples	NULL
containing	NULL
the	NULL
39	NULL
and	NULL
40	NULL
kDa	NULL
polypeptides	NULL
generated	NULL
the	NULL
specific	NULL
retarded	NULL
band	NULL
in	NULL
a	NULL
gel	NULL
retardation	NULL
assay	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
behavior	NULL
of	NULL
the	NULL
39	NULL
and	NULL
40	NULL
kDa	NULL
polypeptides	NULL
in	NULL
various	NULL
column	NULL
chromatographies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
suggested	NULL
that	NULL
the	NULL
two	NULL
polypeptides	NULL
had	NULL
very	NULL
similar	NULL
biochemical	NULL
properties	NULL
,	NULL
and	NULL
the	NULL
difference	NULL
between	NULL
them	NULL
may	NULL
be	NULL
a	NULL
modification	NULL
such	NULL
as	NULL
phosphorylation	NULL
or	NULL
degradation	NULL
.	NULL

DNA-binding	NULL
properties	NULL
of	NULL
To	NULL
demonstrate	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
the	NULL
purified	NULL
HIV-TFI1	NULL
with	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
a	NULL
DNase	NULL
I	NULL
footprinting	NULL
experiment	NULL
was	NULL
done	NULL
.	NULL

The	NULL
purified	NULL
HIV-TFI	NULL
protected	NULL
a	NULL
region	NULL
corresponding	NULL
to	NULL
nucleotides	NULL
-173	NULL
to	NULL
-159	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
functional	NULL
relationship	NULL
between	NULL
HIV-TF1	NULL
and	NULL
HIV	NULL
EBP	NULL
,	NULL
we	NULL
used	NULL
the	NULL
purified	NULL
HIV-TF1	NULL
and	NULL
the	NULL
purified	NULL
EBP	NULL
in	NULL
a	NULL
DNase	NULL
I	NULL
footprint	NULL
experiment	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
purified	NULL
EBP	NULL
required	NULL
to	NULL
observe	NULL
a	NULL
clear	NULL
footprint	NULL
on	NULL
the	NULL
HIV-1	NULL
LTR	NULL
was	NULL
lower	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
HIV-TF1	NULL
than	NULL
in	NULL
its	NULL
absence	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
3-7	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
binding	NULL
of	NULL
HIV-TFl	NULL
increased	NULL
binding	NULL
of	NULL
the	NULL
factor	NULL
to	NULL
the	NULL
enhancer	NULL
region	NULL
.	NULL

The	NULL
DNA	NULL
sequence	NULL
of	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
USF	NULL
site	NULL
in	NULL
the	NULL
Ad	NULL
MLP	NULL
and	NULL
there	NULL
is	NULL
only	NULL
one	NULL
base	NULL
difference	NULL
out	NULL
of	NULL
10	NULL
nucleotides	NULL
between	NULL
them	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
purified	NULL
HIV-TFI1	NULL
also	NULL
binds	NULL
to	NULL
the	NULL
USF	NULL
site	NULL
,	NULL
a	NULL
gel	NULL
retardation	NULL
analysis	NULL
was	NULL
done	NULL
.	NULL

Both	NULL
probes	NULL
containing	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
of	NULL
HIV	NULL
LTR	NULL
or	NULL
the	NULL
USF	NULL
site	NULL
of	NULL
the	NULL
Ad	NULL
Figure	NULL
5	NULL
.	NULL

Phosphatase	NULL
treatment	NULL
of	NULL
HIV-TF1	NULL
.	NULL

Purified	NULL
HIV-TFI	NULL
was	NULL
treated	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
potato	NULL
acid	NULL
phosphatase	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
DNA-binding	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
gel	NULL
retardation	NULL
assay	NULL
with	NULL
a	NULL
probe	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

In	NULL
a	NULL
control	NULL
experiment	NULL
,	NULL
DNA-binding	NULL
activity	NULL
of	NULL
purified	NULL
HIV	NULL
EBP	NULL
was	NULL
assayed	NULL
in	NULL
a	NULL
similar	NULL
way	NULL
by	NULL
using	NULL
the	NULL
DNA	NULL
probe	NULL
containing	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Arrows	NULL
indicate	NULL
the	NULL
retarded	NULL
band	NULL
corresponding	NULL
to	NULL
specific	NULL
DNA-protein	NULL
complex	NULL
.	NULL

MLP	NULL
bound	NULL
to	NULL
the	NULL
purified	NULL
HIV-TFI	NULL
and	NULL
generated	NULL
a	NULL
specific	NULL
retarded	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
relative	NULL
affinity	NULL
of	NULL
HIV-TFI1	NULL
for	NULL
the	NULL
two	NULL
related	NULL
sequences	NULL
,	NULL
a	NULL
competition	NULL
analysis	NULL
was	NULL
done	NULL
.	NULL

Addition	NULL
of	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
of	NULL
competitor	NULL
containing	NULL
the	NULL
HIV-TF1l-binding	NULL
site	NULL
of	NULL
HIV	NULL
LTR	NULL
partially	NULL
competed	NULL
for	NULL
binding	NULL
of	NULL
HIV-TFI	NULL
to	NULL
the	NULL
HIV-TFI	NULL
probe	NULL
,	NULL
while	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
of	NULL
competitor	NULL
containing	NULL
the	NULL
USF	NULL
site	NULL
abolished	NULL
the	NULL
binding	NULL
of	NULL
HIV-TF1	NULL
completely	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
HIV-TF1	NULL
has	NULL
a	NULL
higher	NULL
affinity	NULL
for	NULL
the	NULL
USF	NULL
site	NULL
than	NULL
the	NULL
HIV-TFI	NULL
site	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Transcriptional	NULL
activation	NULL
by	NULL
purified	NULL
HIV-TFL	NULL
The	NULL
effect	NULL
of	NULL
the	NULL
purified	NULL
HIV-TFI1	NULL
in	NULL
stimulating	NULL
transcription	NULL
was	NULL
examined	NULL
in	NULL
the	NULL
WCE	NULL
of	NULL
HeLa	NULL
cells	NULL
.	NULL

When	NULL
transcribed	NULL
in	NULL
HeLa	NULL
WCE	NULL
,	NULL
the	NULL
pCD12	NULL
plasmid	NULL
DNA	NULL
digested	NULL
with	NULL
EcoRI	NULL
generated	NULL
373	NULL
nucleotide	NULL
run-off	NULL
transcripts	NULL
corresponding	NULL
to	NULL
specific	NULL
initiation	NULL
at	NULL
the	NULL
in	NULL
vitro	NULL
CAP	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
EcoRI-cut	NULL
pRSVCAT	NULL
control	NULL
template	NULL
generated	NULL
291	NULL
nucleotide	NULL
run-off	NULL
transcripts	NULL
.	NULL

Addition	NULL
of	NULL
purified	NULL
HIV-TF1	NULL
stimulated	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
promoter	NULL
2.5-	NULL
to	NULL
4.9-fold	NULL
,	NULL
but	NULL
did	NULL
not	NULL
stimulate	NULL
transcription	NULL
from	NULL
the	NULL
RSV	NULL
LTR	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
1	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
)	NULL
.	NULL

As	NULL
reported	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
,	NULL
addition	NULL
of	NULL
purified	NULL
HIV	NULL
EBP	NULL
stimulated	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
promoter	NULL
4.2-fold	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Interesitingly	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
HIV-TFI	NULL
and	NULL
EBP	NULL
were	NULL
synergistic	NULL
,	NULL
and	NULL
simultaneous	NULL
addition	NULL
of	NULL
both	NULL
proteins	NULL
stimulated	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
promoter	NULL
20-fold	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Disruption	NULL
of	NULL
HIV-TF1-binding	NULL
site	NULL
To	NULL
examine	NULL
whether	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
in	NULL
the	NULL
HIV	NULL
LTR	NULL
functions	NULL
as	NULL
a	NULL
transcriptional	NULL
control	NULL
element	NULL
,	NULL
we	NULL
introduced	NULL
a	NULL
mutation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
By	NULL
using	NULL
a	NULL
gel	NULL
retardation	NULL
analysis	NULL
,	NULL
it	NULL
was	NULL
confirmed	NULL
that	NULL
HIV-TF1	NULL
could	NULL
not	NULL
bind	NULL
to	NULL
this	NULL
mutant	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
,	NULL
The	NULL
mutant	NULL
HIV	NULL
promoter	NULL
was	NULL
linked	NULL
to	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
to	NULL
generate	NULL
the	NULL
plasmid	NULL
pCD-190TFIm	NULL
.	NULL

Two	NULL
CAT	NULL
constructs	NULL
containing	NULL
the	NULL
wild-type	NULL
(	NULL
pCD-190	NULL
)	NULL
or	NULL
mutant	NULL
promoter	NULL
(	NULL
pCD-190TF1Im	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T-cells	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
assayed	NULL
.	NULL

The	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
obtained	NULL
by	NULL
the	NULL
mutant	NULL
promoter	NULL
was	NULL
about	NULL
40	NULL
%	NULL
of	NULL
that	NULL
by	NULL
wild-type	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
1-4	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
PHA	NULL
and	NULL
4	NULL
(	NULL
3-phorobol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
induces	NULL
the	NULL
activation	NULL
of	NULL
HIV	NULL
EBP	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Therfore	NULL
,	NULL
treatment	NULL
of	NULL
cells	NULL
by	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulated	NULL
CAT	NULL
activity	NULL
with	NULL
pCD-190	NULL
about	NULL
10-fold	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
PHA	NULL
and	NULL
PMA	NULL
,	NULL
the	NULL
level	NULL
of	NULL
activity	NULL
with	NULL
mutant	NULL
promoter	NULL
was	NULL
about	NULL
76	NULL
%	NULL
of	NULL
that	NULL
with	NULL
wild-type	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
5-8	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
is	NULL
a	NULL
positive	NULL
element	NULL
for	NULL
transcriptional	NULL
control	NULL
,	NULL
although	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
excess	NULL
of	NULL
activated	NULL
EBP	NULL
,	NULL
the	NULL
HIV-TF1	NULL
site	NULL
appears	NULL
to	NULL
be	NULL
not	NULL
so	NULL
important	NULL
for	NULL
transcription	NULL
of	NULL
HIV-TFI	NULL
.	NULL

©	NULL
Phosphatase	NULL
treatment	NULL
of	NULL
HIV-TF1	NULL
The	NULL
HIV	NULL
EBP	NULL
,	NULL
NF-xB	NULL
,	NULL
is	NULL
activated	NULL
by	NULL
phosphorylation	NULL
of	NULL
its	NULL
inhibitor	NULL
IxB	NULL
(	NULL
22	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
HIV-TFIl	NULL
is	NULL
also	NULL
regulated	NULL
by	NULL
phosphorylation	NULL
,	NULL
we	NULL
treated	NULL
the	NULL
purified	NULL
HIV-TFI1	NULL
with	NULL
or	NULL
without	NULL
acid	NULL
phosphatase	NULL
and	NULL
assayed	NULL
them	NULL
in	NULL
parallel	NULL
for	NULL
DNA-binding	NULL
activity	NULL
.	NULL

DNA-binding	NULL
activity	NULL
was	NULL
greatly	NULL
reduced	NULL
by	NULL
phosphatase	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

In	NULL
a	NULL
control	NULL
experiment	NULL
,	NULL
the	NULL
purified	NULL
HIV	NULL
EBP	NULL
was	NULL
treated	NULL
with	NULL
phosphatase	NULL
and	NULL
its	NULL
DNA-binding	NULL
activity	NULL
was	NULL
examined	NULL
.	NULL

Although	NULL
the	NULL
mobility	NULL
of	NULL
protein-DNA	NULL
complex	NULL
was	NULL
changed	NULL
,	NULL
no	NULL
change	NULL
in	NULL
the	NULL
DNA-binding	NULL
activity	NULL
was	NULL
detected	NULL
after	NULL
phosphatase	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
phosphorylation	NULL
of	NULL
HIV-TF1	NULL
appeared	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
its	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

17	NULL
4693	NULL
DISCUSSION	NULL
We	NULL
have	NULL
purified	NULL
the	NULL
protein	NULL
HIV-TFI1	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
specific	NULL
site	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
stimulates	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
promoter	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
DNA	NULL
sequence	NULL
of	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
USF	NULL
site	NULL
in	NULL
the	NULL
Ad	NULL
MLP	NULL
,	NULL
and	NULL
only	NULL
one	NULL
base	NULL
out	NULL
of	NULL
10	NULL
is	NULL
different	NULL
between	NULL
the	NULL
two	NULL
sequences	NULL
.	NULL

Although	NULL
a	NULL
sequence	NULL
homologous	NULL
with	NULL
USF	NULL
site	NULL
in	NULL
the	NULL
HIV	NULL
LTR	NULL
was	NULL
noted	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
,	NULL
our	NULL
report	NULL
probably	NULL
gave	NULL
the	NULL
first	NULL
evidence	NULL
showing	NULL
that	NULL
the	NULL
factor	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
stimulates	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

The	NULL
molecular	NULL
weight	NULL
of	NULL
purified	NULL
HIV-TF1	NULL
was	NULL
39,000	NULL
and	NULL
40,000	NULL
and	NULL
is	NULL
indistinguishable	NULL
from	NULL
that	NULL
of	NULL
purified	NULL
USF	NULL
from	NULL
HeLa	NULL
cells	NULL
,	NULL
43,000	NULL
and	NULL
44,000	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
purified	NULL
HIV-TFI	NULL
bound	NULL
to	NULL
the	NULL
USF	NULL
site	NULL
in	NULL
the	NULL
Ad	NULL
MLP	NULL
,	NULL
and	NULL
was	NULL
perfectly	NULL
stable	NULL
at	NULL
temperatures	NULL
as	NULL
high	NULL
as	NULL
100°C	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
like	NULL
purified	NULL
USF	NULL
(	NULL
37	NULL
)	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
suggest	NULL
that	NULL
HIV-TFI	NULL
is	NULL
identical	NULL
or	NULL
closely	NULL
related	NULL
to	NULL
USF	NULL
.	NULL

Recently	NULL
,	NULL
cDNA	NULL
clones	NULL
encoding	NULL
USF	NULL
have	NULL
been	NULL
isolated	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
another	NULL
protein	NULL
,	NULL
TEF3	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
USF	NULL
site	NULL
in	NULL
the	NULL
Ad	NULL
MLP	NULL
was	NULL
also	NULL
identifited	NULL
by	NULL
cDNA	NULL
cloning	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Both	NULL
proteins	NULL
contain	NULL
a	NULL
helix-loop-helix	NULL
and	NULL
a	NULL
leucine	NULL
zipper	NULL
structure	NULL
,	NULL
but	NULL
the	NULL
sequence	NULL
of	NULL
USF	NULL
is	NULL
totaly	NULL
different	NULL
from	NULL
that	NULL
of	NULL
TEF3	NULL
.	NULL

Thus	NULL
,	NULL
multiple	NULL
proteins	NULL
which	NULL
bind	NULL
to	NULL
the	NULL
USF	NULL
site	NULL
appear	NULL
to	NULL
exist	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
possibility	NULL
that	NULL
HIV-TFI	NULL
is	NULL
different	NULL
from	NULL
USF	NULL
remains	NULL
.	NULL

Using	NULL
a	NULL
transfection	NULL
assay	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
HIV	NULL
promoter	NULL
containing	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
has	NULL
a	NULL
reduced	NULL
activity	NULL
,	NULL
about	NULL
40	NULL
%	NULL
of	NULL
that	NULL
of	NULL
wild-type	NULL
promoter	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
activated	NULL
by	NULL
PHA	NULL
and	NULL
PMA	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
disruption	NULL
of	NULL
the	NULL
HIV-TF1-binding	NULL
site	NULL
on	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
was	NULL
lower	NULL
than	NULL
that	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PHA	NULL
and	NULL
PMA	NULL
.	NULL

Since	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
increased	NULL
the	NULL
level	NULL
of	NULL
activated	NULL
HIV	NULL
EBP	NULL
,	NULL
may	NULL
not	NULL
dramatically	NULL
affect	NULL
HIV	NULL
transcription	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
saturating	NULL
amount	NULL
of	NULL
EBP	NULL
.	NULL

Thus	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
HIV-TFI	NULL
may	NULL
be	NULL
a	NULL
key	NULL
regulator	NULL
only	NULL
when	NULL
the	NULL
level	NULL
of	NULL
EBP	NULL
is	NULL
low	NULL
,	NULL
such	NULL
as	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
.	NULL

Phosphatase	NULL
treatment	NULL
of	NULL
the	NULL
purified	NULL
HIV-TFI	NULL
greatly	NULL
reduced	NULL
its	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
some	NULL
extracellur	NULL
stimuli	NULL
,	NULL
which	NULL
leads	NULL
to	NULL
virus	NULL
production	NULL
from	NULL
latently	NULL
infected	NULL
cells	NULL
,	NULL
may	NULL
activate	NULL
HIV	NULL
transcription	NULL
partly	NULL
by	NULL
phosphorylation	NULL
of	NULL
HIV-TFI1	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Takashi	NULL
Okamoto	NULL
and	NULL
Shigehisa	NULL
Mori	NULL
for	NULL
plasmid	NULL
pCD12	NULL
and	NULL
helpful	NULL
advice	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Barre-Sinousi	NULL
,	NULL
F.	NULL
,	NULL
Chermann	NULL
,	NULL
J.	NULL
,	NULL
Rey	NULL
,	NULL
R.	NULL
,	NULL
Nugeryte	NULL
,	NULL
M.	NULL
,	NULL
Chamaret	NULL
,	NULL
S.	NULL
,	NULL
Gruest	NULL
,	NULL
J.	NULL
,	NULL
Dauget	NULL
,	NULL
C.	NULL
,	NULL
Axler-Blin	NULL
,	NULL
C.	NULL
,	NULL
Vezinet-Brun	NULL
,	NULL
F.	NULL
,	NULL
Rouzioux	NULL
,	NULL
C.	NULL
,	NULL
Rosenbaum	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Montagnier	NULL
,	NULL
L.	NULL
(	NULL
1983	NULL
)	NULL
Science	NULL
,	NULL
220	NULL
,	NULL
868-871	NULL
.	NULL

2	NULL
.	NULL

Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Salahuddin	NULL
,	NULL
S.	NULL
Z.	NULL
,	NULL
Popovic	NULL
,	NULL
M.	NULL
,	NULL
Shearer	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Kaplan	NULL
,	NULL
M.	NULL
,	NULL
Haynes	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
Palker	NULL
,	NULL
Y.	NULL
J.	NULL
,	NULL
Redfield	NULL
,	NULL
R.	NULL
,	NULL
Oleske	NULL
,	NULL
J.	NULL
,	NULL
Safai	NULL
,	NULL
B.	NULL
,	NULL
White	NULL
,	NULL
G.	NULL
,	NULL
Foster	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Markham	NULL
,	NULL
P.	NULL
D.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
,	NULL
224	NULL
,	NULL
500-503	NULL
.	NULL

3	NULL
.	NULL

Popovic	NULL
,	NULL
M.	NULL
,	NULL
Sarngardharan	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Read	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
,	NULL
224	NULL
,	NULL
497-500	NULL
.	NULL

4	NULL
.	NULL

Sarngardharan	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Popovic	NULL
,	NULL
M.	NULL
,	NULL
Bruch	NULL
,	NULL
L.	NULL
,	NULL
Schupbach	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
,	NULL
224	NULL
,	NULL
506-508	NULL
.	NULL

5	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
,	NULL
Guo	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Haseltine	NULL
,	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
Science	NULL
,	NULL
227	NULL
,	NULL
171-173	NULL
.	NULL

6	NULL
.	NULL

Sodroski	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Patarca	NULL
,	NULL
R.	NULL
,	NULL
Rosen	NULL
,	NULL
C.	NULL
,	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Haseltine	NULL
,	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
Science	NULL
,	NULL
229	NULL
,	NULL
74-77	NULL
.	NULL

4694	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

17	NULL
26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

+35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

39.	NULL
.	NULL

Sodroski	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Goh	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Rosen	NULL
,	NULL
C.	NULL
,	NULL
Dayton	NULL
,	NULL
A..	NULL
Terwilliger	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Haseltine	NULL
,	NULL
W.	NULL
(	NULL
1986	NULL
)	NULL
Nature	NULL
,	NULL
321	NULL
,	NULL
412-417.	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Kadonaga	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Luciw	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Science	NULL
,	NULL
232	NULL
,	NULL
755-759.	NULL
.	NULL

Dinter	NULL
,	NULL
H.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Karin	NULL
,	NULL
M..	NULL
and	NULL
Jones	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
6	NULL
,	NULL
4067-4071.	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Wu	NULL
,	NULL
F.	NULL
K.	NULL
,	NULL
Mitsuyasu	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Gaynor	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
,	NULL
6	NULL
,	NULL
3761-3770.	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
,	NULL
326	NULL
,	NULL
711-713.	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
,	NULL
47	NULL
,	NULL
921-928.	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Genes	NULL
&	NULL
Dev..	NULL
3	NULL
,	NULL
1689-1698.	NULL
.	NULL

Kawakami	NULL
,	NULL
K.	NULL
,	NULL
Scheidereit	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A.	NULL
,	NULL
85	NULL
,	NULL
4700-4704.	NULL
.	NULL

Yano	NULL
,	NULL
O.	NULL
,	NULL
Kanellopoulos	NULL
,	NULL
J.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
LeBail	NULL
.	NULL

O.	NULL
,	NULL
Israel	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Kourilsky	NULL
,	NULL
P.	NULL
(	NULL
1987	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
6	NULL
,	NULL
3317-3324.	NULL
.	NULL

Maekawa	NULL
,	NULL
T.	NULL
,	NULL
Itoh	NULL
,	NULL
F.	NULL
,	NULL
Okamoto	NULL
,	NULL
T.	NULL
,	NULL
Kurimoto	NULL
,	NULL
F.	NULL
,	NULL
Imamoto	NULL
,	NULL
F..	NULL
and	NULL
Ishii	NULL
,	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
264	NULL
,	NULL
2826-2831.	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
Sharp	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol..	NULL
7	NULL
,	NULL
305-312.	NULL
.	NULL

Clark	NULL
,	NULL
L.	NULL
,	NULL
Pollock	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Hay	NULL
,	NULL
R.	NULL
T.	NULL
(	NULL
1988	NULL
)	NULL
Genes	NULL
&	NULL
Dev..	NULL
2	NULL
,	NULL
991-1002.	NULL
.	NULL

Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Josephs	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Gilman	NULL
,	NULL
M.	NULL
Z.	NULL
,	NULL
Ryan	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Clarkson	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
,	NULL
330	NULL
,	NULL
391-394.	NULL
.	NULL

Bacverle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
,	NULL
53	NULL
,	NULL
211-217.	NULL
.	NULL

Bagcuerle	NULL
,	NULL
P.	NULL
A..	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
,	NULL
242	NULL
,	NULL
540-546.	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
,	NULL
344	NULL
,	NULL
678-682.	NULL
.	NULL

Maekawa	NULL
,	NULL
T.	NULL
,	NULL
Sakura	NULL
,	NULL
H.	NULL
,	NULL
Sudo	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Ishii	NULL
,	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Bio/	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
264	NULL
,	NULL
14591-14593.	NULL
.	NULL

Fan	NULL
,	NULL
C.-M.	NULL
,	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

,	NULL
4	NULL
,	NULL
29-42.	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
LeClair	NULL
,	NULL
K.	NULL
P.	NULL
,	NULL
Singh	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Sharp	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
1406-1414	NULL
.	NULL

Rustgi	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
Va	NULL
n't	NULL
Veer	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
and	NULL
Bernards	NULL
,	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

U.S.A.	NULL
,	NULL
87	NULL
,	NULL
8707-8710	NULL
.	NULL

Nomura	NULL
,	NULL
N.	NULL
,	NULL
Zhao	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
Nagase	NULL
,	NULL
T.	NULL
,	NULL
Maekawa	NULL
,	NULL
T..	NULL
Ishizaki	NULL
,	NULL
R..	NULL
Tabata	NULL
.	NULL

S.	NULL
,	NULL
and	NULL
Ishii	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
266	NULL
,	NULL
8590-8594	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
Blank	NULL
,	NULL
V.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Vandekerckhove	NULL
,	NULL
J.	NULL
,	NULL
Lottspeich	NULL
,	NULL
F.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Urvan	NULL
,	NULL
M.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
,	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
62	NULL
,	NULL
1007-1018	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Gifford	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Riviere	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
62	NULL
,	NULL
1019-1029	NULL
.	NULL

Sawadogo	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1986	NULL
)	NULL
In	NULL
Grodzicker	NULL
,	NULL
T.	NULL
,	NULL
Sharp	NULL
,	NULL
P..	NULL
and	NULL
Botchan	NULL
,	NULL
M	NULL
.	NULL

(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Cancer	NULL
Cells/DNA	NULL
Tumor	NULL
Viruses	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
,	NULL
Vol	NULL
.	NULL

4	NULL
,	NULL
pp147-154	NULL
.	NULL

Kadonaga	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
,	NULL
83	NULL
,	NULL
5589-5893	NULL
.	NULL

Okamoto	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
,	NULL
47	NULL
,	NULL
29-35	NULL
.	NULL

Wu	NULL
,	NULL
C.	NULL
,	NULL
Wilson	NULL
,	NULL
S.	NULL
,	NULL
Salker	NULL
,	NULL
B.	NULL
,	NULL
Dawid	NULL
,	NULL
I.	NULL
,	NULL
Paisley	NULL
,	NULL
T..	NULL
Zimarino	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Ueda	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Science	NULL
,	NULL
238	NULL
,	NULL
1247-1253	NULL
.	NULL

Neumann	NULL
,	NULL
E.	NULL
,	NULL
Schaefer-Ridder	NULL
,	NULL
M.	NULL
,	NULL
Wang	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Hofschneider	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
1	NULL
,	NULL
§41-§47	NULL
.	NULL

Edlund	NULL
,	NULL
T.	NULL
,	NULL
Walker	NULL
,	NULL
M.	NULL
D..	NULL
Barr	NULL
.	NULL

P.	NULL
J..	NULL
and	NULL
Rutter	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Science	NULL
.	NULL

230	NULL
,	NULL
912-916	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M..	NULL
Moffat	NULL
,	NULL
L.	NULL
F.	NULL
,	NULL
and	NULL
Howard	NULL
,	NULL
B.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
1044-1051	NULL
.	NULL

Sawadogo	NULL
,	NULL
M.	NULL
,	NULL
Van	NULL
Dyke	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Gregor	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
and	NULL
Reder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
263	NULL
,	NULL
11985-11993.	NULL
.	NULL

Gregor	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Sawadogo	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
.	NULL

R.	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
Genes	NULL
&	NULL
Dev..	NULL
4	NULL
,	NULL
1730-1740	NULL
.	NULL

Beckmann	NULL
,	NULL
H.	NULL
,	NULL
Su	NULL
,	NULL
L.-K..	NULL
and	NULL
Kadesch	NULL
,	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
Genes	NULL
&	NULL
Dev..	NULL
4	NULL
,	NULL
167-179	NULL
.	NULL

